Pre-Recorded

Plenary Presentation

ILD and Friends

Management of lung cancers with underlying interstitial lung diseases has unique challenges. During this 60-minute session, divided into 4 separate lectures, we will discuss the incidence and epidemiology of lung cancers in this population, the role of biologics and chemotherapy effects, and radiation therapy and associated complications with underlying ILD. In addition, use of genomic classifier and surgical considerations will be covered. The goal is to review the importance of early diagnosis of cancers and discuss common drugs that can both cause or worsen ILD to help guide safe drug choice and recognition of pulmonary adverse effects of these drugs.

Review incidence of lung cancer in ILA/ILD patients and association of increased cancer risk with certain subtypes.

Select chemotherapy and biologics based on underlying ILD and possible pulmonary complications.